Evogene (EVGN)

• Market cap: $9.21M
• 1 day: -9.21%
• 5 days: 26.61%
• 1 month: 13.11%
• 3 months: 0.00%
• 6 months: 0.73%
• Year to date: -28.87%
• 1 year: -78.96%
• 5 years: -86.73%
• 10 years: -98.51%
• Sector: Healthcare
• Industry: Biotechnology

About: Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules, and genetic elements as the core components for such products. It holds several subsidiaries utilizing the CPB platform for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits, and ag-solutions for castor oil production. It generates maximum revenue from the Agriculture segment, followed by Industry.

Employees: 75

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

67% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 3

50% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 2

7% more funds holding

Funds holding: 15 [Q4 2024] → 16 (+1) [Q1 2025]

0.4% more ownership

Funds ownership: 5.92% [Q4 2024] → 6.32% (+0.4%) [Q1 2025]

30% less capital invested

Capital invested by funds: $752K [Q4 2024] → $527K (-$225K) [Q1 2025]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $3.50 154% upside
• Avg. target: $3.50 154% upside
• High target: $3.50 154% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Lake Street Ben Klieve

154% upside $3.50

Buy Maintained

22 May 2025